ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD)

AstraZeneca to Leverage ArcherDX's PCM Liquid Biopsy Technology to Facilitate Multiple Clinical Trials for Early-Stage Non-Small Cell Lung Cancer Therapies BOULDER, Colo., May 26, 2020 -- (Healthcare Sales & Marketing Network) -- ArcherDX, Inc., today ... Biopharmaceuticals, Diagnostics, Oncology ArcherDX, AstraZeneca, Anchored Multiplex PCR, Personalized Cancer Monitoring
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news